focus -WSS

focus

author：focus 2025-10-02 00:51:49 - browse：1

Rising drug prices —Medicare coverage from STAT — Medicare on Friday released new details about how its new drug price negotiation program will work, just two months before it’s set to start. APStock

WASHINGTON — Medicare on Friday released new details about how its new drug price negotiation program will work, just two months before it’s set to start.

Medicare released an initial outline of how the program will work in March. Some parts, including the outline of how drugs would be selected for the negotiation process, were immediately final. The agency asked drug companies, patients, and other affected parties to weigh in on other parts about how the process would proceed, what factors would be considered, and how drugmakers would be held accountable.

Newsletters

Sign up for D.C. Diagnosis

An insider's guide to the politics and policies of health care

Please enter a valid email address. Privacy Policy

The negotiation process was created last August in Democrats’ drug pricing reform law, and Medicare is supposed to select the first 10 drugs that will be subject to negotiation by Sept. 1.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： AI gets buy

leisure time

WSS

What’s missing from the debate over nursing home staff minimums

Top private equity targets in 2023: cardiology, clinical trials, lasers

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Surgery pushed Ben Carson to fame

Bernie brings in new pharma CEOs to talk drug prices

Readout Newsletter: Amgen, Regeneron, BGI Group and more

leisure time

focus

Sign up for D.C. Diagnosis

leisure time

Psychedelics group wrestles with new pharma identity

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Walensky prepares to leave CDC — and Congress — behind

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Bright Health sells Medicare Advantage business to Molina

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Tori Bowie and the unacceptable rates of Black maternal death

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

23andMe had bad news about my health. I wish a person had delivered it

Why Novartis is going to walk from its acquisition of MorphoSys

leisure time

HIV drugs protect against transmission, even in unprotected sex

Readout Newsletter: Amgen, Regeneron, BGI Group and more

340B reform proposal comes out of Senate working group

AstraZeneca stays mum on Medicare drug pricing negotiations

Updated Covid vaccine has 54% effectiveness, new study suggests

See how much Covid

focus

leisure time

Wikipedia

knowledge